147 related articles for article (PubMed ID: 36498511)
1. PRAME Immuno-Expression in Cutaneous Sebaceous Carcinoma: A Single Institutional Experience.
Cazzato G; Colagrande A; Ingravallo G; Lettini T; Filoni A; Ambrogio F; Bonamonte D; Dellino M; Lupo C; Casatta N; Resta L; Maiorano E; Cascardi E; Marzullo A
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498511
[TBL] [Abstract][Full Text] [Related]
2. Periocular Sebaceous Carcinoma: A Case Audit from the National Specialist Ophthalmic Pathology Service in Liverpool from 2009 to 2022 to Assess the Diagnostic Utility of PRAME Expression.
Salleh AA; Krishna Y; Coupland SE
Ocul Oncol Pathol; 2024 Apr; 10(1):1-8. PubMed ID: 38645737
[TBL] [Abstract][Full Text] [Related]
3. PRAME Immunoexpression in 275 Cutaneous Melanocytic Lesions: A Double Institutional Experience.
Cazzato G; Cascardi E; Colagrande A; Belsito V; Lospalluti L; Foti C; Arezzo F; Dellino M; Casatta N; Lupo C; Buongiorno L; Stellacci A; Marrone M; Ingravallo G; Maiorano E; Resta L
Diagnostics (Basel); 2022 Sep; 12(9):. PubMed ID: 36140597
[TBL] [Abstract][Full Text] [Related]
4. Androgen Receptor Immunohistochemistry is Superior to PRAME for the Differentiation of Sebaceous Carcinoma From Primary Cutaneous Basaloid Mimics.
Wakefield C; Russell-Goldman E
Am J Dermatopathol; 2024 Apr; 46(4):195-203. PubMed ID: 38488347
[TBL] [Abstract][Full Text] [Related]
5. Comparison of adipophilin and recently introduced PReferentially expressed Antigen in MElanoma immunohistochemistry in the assessment of sebaceous neoplasms: A pilot study.
Donnell SA; LeBlanc RE; Yan S; Parra O; Momtahen S; Sriharan A; Linos K
J Cutan Pathol; 2021 Oct; 48(10):1252-1261. PubMed ID: 33949693
[TBL] [Abstract][Full Text] [Related]
6. PRAME immunostain expression in sebaceous lesions, cutaneous carcinomas and adnexal structures.
Ng JKM; Choi PCL; Chow C; Li JJX; Chan AWS; Cheung CMT; Ip ECC; Ng HK; To KF
Pathology; 2022 Oct; 54(6):721-728. PubMed ID: 35644638
[TBL] [Abstract][Full Text] [Related]
7. Preferentially expressed antigen in melanoma expression in nonmelanoma skin cancers and melanocytes in surrounding skin.
Elsensohn A; Hanson J; Ferringer T
J Cutan Pathol; 2021 Sep; 48(9):1150-1155. PubMed ID: 33719089
[TBL] [Abstract][Full Text] [Related]
8. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics.
Rawson RV; Shteinman ER; Ansar S; Vergara IA; Thompson JF; Long GV; Scolyer RA; Wilmott JS
Pathology; 2022 Dec; 54(7):863-873. PubMed ID: 35987723
[TBL] [Abstract][Full Text] [Related]
10. PRAME/MELAN-A double immunostaining as a diagnostic tool for conjunctival melanocytic lesions: A South American experience.
Carvajal P; Zoroquiain P
Pathol Res Pract; 2023 Oct; 250():154776. PubMed ID: 37696245
[TBL] [Abstract][Full Text] [Related]
11. Use of PRAME immunostaining to distinguish early melanoma in situ from benign pigmented conditions.
Olds H; Utz S; Abrams J; Terrano D; Mehregan D
J Cutan Pathol; 2022 Jun; 49(6):510-514. PubMed ID: 35146798
[TBL] [Abstract][Full Text] [Related]
12. PReferentially Expressed Antigen in MElanoma (PRAME): preliminary communication on a translational tool able to early detect Oral Malignant Melanoma (OMM).
Cascardi E; Cazzato G; Ingravallo G; Dellino M; Lupo C; Casatta N; Ballini A; Pacifici A; Marenzi G; Sammartino G; Maiorano E; Tatullo M
J Cancer; 2023; 14(4):628-633. PubMed ID: 37057287
[TBL] [Abstract][Full Text] [Related]
13. [Application of immunohistochemical staining of PRAME in differential diagnosis between melanoma and melanocytic nevus].
Du J; Yu WJ; Guo RP; Su J
Zhonghua Bing Li Xue Za Zhi; 2022 Jul; 51(7):621-626. PubMed ID: 35785832
[No Abstract] [Full Text] [Related]
14. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
Lezcano C; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
[TBL] [Abstract][Full Text] [Related]
15. Preferentially expressed Antigen in MElanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation.
Fattori A; de la Fouchardière A; Cribier B; Mitcov M
Hum Pathol; 2022 Mar; 121():19-28. PubMed ID: 34990622
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemistry for Preferentially Expressed Antigen in Melanoma in the Differential Diagnosis of Melanocytic Lesions of the Nail Apparatus.
Krajisnik A; Gharavi NM; Faries MB; Balzer BL; Frishberg DP; Martelli M; Shon W
Am J Dermatopathol; 2022 Jul; 44(7):488-492. PubMed ID: 35120028
[TBL] [Abstract][Full Text] [Related]
17. PRAME expression in melanocytic lesions of the nail.
Parra O; Linos K; Li Z; Yan S
J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053
[TBL] [Abstract][Full Text] [Related]
18. PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation.
Kline N; Menge TD; Hrycaj SM; Andea AA; Patel RM; Harms PW; Chan MP; Bresler SC
Am J Dermatopathol; 2022 Jun; 44(6):404-410. PubMed ID: 34991102
[TBL] [Abstract][Full Text] [Related]
19. PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid Melanoma.
Glutsch V; Wobser M; Schilling B; Gesierich A; Goebeler M; Kneitz H
Dermatopathology (Basel); 2022 May; 9(2):148-157. PubMed ID: 35645230
[TBL] [Abstract][Full Text] [Related]
20. PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis.
Hrycaj SM; Szczepanski JM; Zhao L; Siddiqui J; Thomas DG; Lucas DR; Patel RM; Harms PW; Bresler SC; Chan MP
Histopathology; 2022 Dec; 81(6):818-825. PubMed ID: 36102613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
